Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma.
Phioanh Leia NghiemphuJeremie VitteEva DombiThien NguyenNaveed WagleAkira IshiyamaAli R SepahdariDavid CachiaBrigitte C WidemannDerald E BrackmannJoni K DohertyMichel KalamaridesMarco GiovanniniPublished in: Journal of neuro-oncology (2024)
Volumetric imaging at 3 months can serve as an early biomarker to predict long-term sensitivity to everolimus treatment. Everolimus may represent a safe treatment option to decrease the growth of NF2-related VS in patients who have stable hearing and neurological condition. TRN: NCT01345136 (April 29, 2011).
Keyphrases
- signaling pathway
- high resolution
- end stage renal disease
- chronic kidney disease
- oxidative stress
- lps induced
- multiple sclerosis
- ejection fraction
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- nuclear factor
- mass spectrometry
- photodynamic therapy
- brain injury
- hearing loss
- toll like receptor
- cerebral ischemia